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ABSTRACT
We proposed that: 1) persistent spontaneous necroptosis in a very small number of hematopoietic cells might be the cause of BMF syndromes; 2) necroptotic cells release molecules which trigger the onset of T cell-dependent adaptive immune reactions causing BMF syndromes; 3) immune cells suppress BM hematopoiesis by producing inflammatory cytokines, including IFN-gamma and TNF-alpha The dynamic alteration of IFN-gamma and TNF-alpha levels might determine disease progression in BMF syndromes. Introduction:
Prior exposure to certain chemicals or infections may contribute to the development of some of bone marrow failure (BMF) syndromes. Cryptic clonal genetic lesions from somatic mutations have been detected in BMF patients' cells. In most cases, such mutant cells in BMF represent only a very small percentage of a patient's bone marrow (BM) cells. Many BMF syndromes can evolve into clonal disorders and can progress to leukemia. An inflammatory mechanism of hematopoietic repression based on autoimmune conditions has been proposed to explain the pathogenic physiology of most if not all BMF syndromes. However, whether and how chemicals/infections and the small percentage of mutant cells actually induce these immune-inflammatory reactions remain unknown. The cellular and molecular effectors of the immune/inflammatory reactions which mediate the repression of normal hematopoiesis and promote the clonal evolution of the mutant cells have still not been completely identified due to a lack of appropriate and effective animal models.
We believe that our Mx1Cre Experiments designed for this Aim are delayed because our Rip3 -/-mice were infected by norovirus. By collaborating with the transgenic animal facility at Northwestern University, we were able to clear the norovirus from the Rip3 -/-mouse line by rederivation. We crossed the Rip3 -/-mice with C + Tak fx mice. Currently, we have obtained the first batch of double-mutant mice. We are in the process of expanding the mice for analysis. We predict that we should be able to complete the experiments designed for this Aim by early next year. We have purchased Ifn-γ -/-mice from the Jax laboratory. We crossed the Ifn-γ -/-mice with Tak1/Tnfr compound-knockout mice. Currently, we have obtained several mice which show deletion of all 3 genes. We are in the process of analyzing these mice. We predict that we should be able to complete the experiments designed for this Aim by early next year.
Aim 3: Investigate whether immune-mediated hematopoietic destruction contributes to the pathogenesis of BMF in C + Tak fx mice. We will examine the degree to which BMF can be prevented by anti-T lymphocyte immunosuppressive therapy.
Significant progress has been made in this specific Aim. To determine the potential autoimmune-related BMF in Tak1/Tnfr compound-knockout mice, we further examined the changes of immune cells in Tak1/Tnfr compound-knockout BMF mice. We found a significant increase in CD44 high CD62L low memory CD4 + lymphocytes (Fig. 1) , CD69 + CD25 + activating CD4 + T cells (Fig. 2) , Th1 and IL-10 + T lymphocytes (Fig. 3 ) but a reduction of repressive Th2 cells (Fig. 3) in Tak1/Tnfr compound-knockout mice compared to wild type (WT) littermate controls. However, Th17 and CD4 + CD25 + Foxo3 + Treg cells are comparable between Tak1/Tnfr compound-knockout mice and WT control mice (data not shown).
To test whether this increase in CD4 + T lymphocytes is the cause of BMF in Tak1/Tnfr compound-knockout mice, following the development of BMF, we injected the mice with 250µg of anti-CD4 antibody every week for a total of 4 weeks. By examining the percentage of CD4 + cells after the mice were euthanized, we found that a significant reduction of CD4 + T cells in peripheral blood, spleens and bone marrow of the anti-CD4 injected mice compared to isotype antibody-injected controls and WT mice, suggesting the success of CD4 T cell depletion by such antibody injection (Fig. 4) . By carefully analyzing the animals, we demonstrated that anti-CD4 antibody injection can almost completely cure the BMF in Tak1/Tnfr compound-knockout BMF (Fig. 5) , as shown by restoration of body weight and hematopoietic cells. Currently we are in the process of evaluating the role of CD8 + cells in the pathogenesis of BMF in Tak1/Tnfr compound-knockout mice by depleting CD8 + T cells using anti-CD8 antibody injection. We also isolated CD4 + T cells from Tak1/Tnfr compound-knockout mice and injected these cells into WT mice to determine whether we can induce BMF using such activated CD4 + cells. 
Research Accomplishments: Aim 1:
We were able to obtain the first batch Rip3 -/-C + Tak fx compound-mutant mice. We are in the process of expanding these mice and preparing them for analysis.
Aim 2:
We obtained the several Ifnr -/-C + Tak fx Tnfr -/-compound-mutant mice. We are in the process of expanding these mice and preparing them for analysis.
Aim 3:
We further verified the immune parameters in the C 
Conclusion:
The progression of the project is moving smoothly. As of now, the only technical problem we have encountered is the noroviral infection of Rip3 -/-mice, which has been rectified. We predict that we can complete all of the designed experiments within the originally-proposed time frame. 
